|
Market Closed -
NYSE
16:00:02 2026-11-18 EST
|
5-day change | 1st Jan Change | ||
| 70.53 USD | +0.77% |
|
-6.45% | -19.22% |
| 11-18 | Globus Medical, Inc. Presents at Jefferies London Healthcare Conference, Nov-18-2026 11:30 AM | |
| 11-13 | Globus Medical Insider Sold Shares Worth $3,131,547, According to a Recent SEC Filing | MT |
| Market Cap | 9.27B 8.46B 7.82B 7.06B 13.29B 866B 13.81B 94.42B 37.33B 468B 34.78B 34.05B 1,477B | P/E 2026 * |
16.9x | P/E 2027 * | 15.2x |
|---|---|---|---|---|---|
| Enterprise Value | 8.45B 7.71B 7.12B 6.43B 12.11B 790B 12.59B 86.05B 34.01B 426B 31.7B 31.03B 1,346B | EV / Sales 2026 * |
2.72x | EV / Sales 2027 * | 2.46x |
| Free-Float |
82.03% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| GMED | Delayed | |
| GMED | Real-time | ||
| GM0N | Real-time | ||
| GMED * | End-of-day quote | ||
| GM0N | Real-time | ||
| GM0N | Delayed | ||
| GM0N | Delayed | ||
| GM0N | Delayed |
Last Transcript: Globus Medical, Inc.
| 1 day | +0.77% | ||
| 1 week | -6.45% | ||
| Current month | -9.63% | ||
| 1 month | -8.06% | ||
| 3 months | -18.41% | ||
| 6 months | -10.64% | ||
| Current year | -19.22% |
| 1 week | 69.02 | 73.45 | |
| 1 month | 69.02 | 88.1 | |
| Current year | 69.02 | 101.4 | |
| 1 year | 69.02 | 101.4 | |
| 3 years | 44.02 | 101.4 | |
| 5 years | 43.38 | 101.4 | |
| 10 years | 20.81 | 101.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Keith Pfeil
CEO | Chief Executive Officer | 47 | 2025-07-17 |
Kyle Kline
DFI | Director of Finance/CFO | 41 | 2025-07-17 |
Brian Kearns
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
David Paul
CHM | Chairman | 59 | 2002-12-31 |
David Davidar
BRD | Director/Board Member | 60 | 2002-12-31 |
Daniel Lemaitre
BRD | Director/Board Member | 72 | 2011-04-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/4/26 | Sell | Director | -5,000 | 0.0044% | ||
| 9/15/26 | Exercice | Director | 90,000 | 0.0805% | ||
| 8/18/26 | Exercice | Director | 75,000 | 0.0662% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.77% | -6.45% | -15.45% | +54.77% | 9.27B | ||
| -0.22% | -4.40% | -19.63% | +4.95% | 181B | ||
| -1.56% | -0.88% | -0.08% | +34.72% | 125B | ||
| +0.19% | -0.20% | -11.51% | +10.32% | 121B | ||
| +1.12% | -0.96% | -41.94% | +0.79% | 90.52B | ||
| -0.64% | -0.45% | -3.69% | +78.62% | 66.9B | ||
| +0.31% | +0.73% | +12.35% | -7.37% | 58.68B | ||
| +1.19% | -0.59% | +4.22% | +50.63% | 54.38B | ||
| +0.86% | -1.59% | +1.78% | +38.65% | 48.46B | ||
| +0.84% | +4.77% | +3.97% | -0.26% | 35.4B | ||
| Average | +0.43% | -1.29% | -7.00% | +26.58% | 79B | |
| Weighted average by Cap. | +0.24% | -1.59% | -10.07% | +20.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.11B 2.83B 2.62B 2.37B 4.45B 290B 4.63B 31.65B 12.51B 157B 11.66B 11.42B 495B | 3.28B 2.99B 2.77B 2.5B 4.7B 307B 4.89B 33.41B 13.21B 165B 12.31B 12.05B 522B |
| Net income | 567M 517M 478M 431M 812M 52.95B 844M 5.77B 2.28B 28.58B 2.13B 2.08B 90.25B | 626M 571M 528M 476M 897M 58.5B 933M 6.38B 2.52B 31.58B 2.35B 2.3B 99.71B |
| Net Debt | -822M -750M -693M -626M -1.18B -76.85B -1.23B -8.38B -3.31B -41.48B -3.09B -3.02B -131B | -1.2B -1.09B -1.01B -910M -1.71B -112B -1.78B -12.18B -4.82B -60.34B -4.49B -4.39B -191B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-18 | US$70.53 | +0.77% | 1,427,322 |
| 26-11-17 | US$69.99 | -0.72% | 1,140,847 |
| 26-11-16 | US$70.50 | -2.27% | 1,375,325 |
| 26-11-13 | US$72.14 | -0.22% | 1,549,142 |
| 26-11-12 | US$72.30 | -4.10% | 1,694,661 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- GMED Stock
Select your edition
All financial news and data tailored to specific country editions
















